Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shusuke Yoshikawa

Showing results (41-50 of 74) with videos related to

Pageof 8
Sort By:
Japanese Journal of Clinical Oncology|November 15, 2017
Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON)Kenjiro Namikawa, Arata Tsutsumida, Tomonori Mizutani, et al.
Cancer Immunology, Immunotherapy : CII|June 19, 2012
Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assayYasuto Akiyama, Masaru Komiyama, Yoji Nakamura, et al.
The Journal of Dermatology|August 20, 2020
Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanomaKenjiro Namikawa, Yoshio Kiyohara, Tatsuya Takenouchi, et al.
The Journal of Dermatology|April 29, 2017
Melanoma patient response to nivolumab treatment for metastatic lung lesions: Multi-OMICS analysis in Project HOPEYoshio Kiyohara, Shusuke Yoshikawa, Masaki Otsuka, et al.
Cancer Genomics & Proteomics|February 26, 2010
Identification of melanoma antigens using a Serological Proteome Approach (SERPA)Ayako Suzuki, Akira Iizuka, Masaru Komiyama, et al.
Oncology Reports|August 17, 2012
Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trialChie Oshita, Masako Takikawa, Akiko Kume, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2018
Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II studyKenjiro Namikawa, Yoshio Kiyohara, Tatsuya Takenouchi, et al.
The Journal of Dermatology|October 23, 2019
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 studyKenji Yokota, Hiroshi Uchi, Hisashi Uhara, et al.
Anticancer Research|March 19, 2017
Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPEShusuke Yoshikawa, Yoshio Kiyohara, Masaki Otsuka, et al.
Cancer Genomics & Proteomics|April 25, 2025
Characterization of the Neoantigen Profile in a Tumor Mutation Burden-high Melanoma Patient With Multiple MetastasesShusuke Yoshikawa, Chie Maeda, Akira Iizuka, et al.
Pageof 8

Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Japanese Journal of Clinical Oncology|November 15, 2017
Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON)Kenjiro Namikawa, Arata Tsutsumida, Tomonori Mizutani, et al.
Cancer Immunology, Immunotherapy : CII|June 19, 2012
Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assayYasuto Akiyama, Masaru Komiyama, Yoji Nakamura, et al.
The Journal of Dermatology|August 20, 2020
Final analysis of a phase II study of nivolumab in combination with ipilimumab for unresectable chemotherapy-naive advanced melanomaKenjiro Namikawa, Yoshio Kiyohara, Tatsuya Takenouchi, et al.
The Journal of Dermatology|April 29, 2017
Melanoma patient response to nivolumab treatment for metastatic lung lesions: Multi-OMICS analysis in Project HOPEYoshio Kiyohara, Shusuke Yoshikawa, Masaki Otsuka, et al.
Cancer Genomics & Proteomics|February 26, 2010
Identification of melanoma antigens using a Serological Proteome Approach (SERPA)Ayako Suzuki, Akira Iizuka, Masaru Komiyama, et al.
Oncology Reports|August 17, 2012
Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trialChie Oshita, Masako Takikawa, Akiko Kume, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2018
Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II studyKenjiro Namikawa, Yoshio Kiyohara, Tatsuya Takenouchi, et al.
The Journal of Dermatology|October 23, 2019
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 studyKenji Yokota, Hiroshi Uchi, Hisashi Uhara, et al.
Anticancer Research|March 19, 2017
Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPEShusuke Yoshikawa, Yoshio Kiyohara, Masaki Otsuka, et al.
Cancer Genomics & Proteomics|April 25, 2025
Characterization of the Neoantigen Profile in a Tumor Mutation Burden-high Melanoma Patient With Multiple MetastasesShusuke Yoshikawa, Chie Maeda, Akira Iizuka, et al.
Pageof 8